RPS6KB2
Ribosomal protein S6 kinase beta-2
As of the edition of 20 October 2026, RPS6KB2 (ribosomal protein S6 kinase beta-2, UniProt Q9UBS0) has 4 drugs tested at it and 4 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UBS0
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Immune system; Urinary and reproductive
- Registered trials of its drugs
- 6
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 3 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| LY-2780301 | Stopped | Phase 2 | none listed |
| Rupitasertib | Went quiet | Phase 1 | none listed |
| TAS0612 | Stopped | Phase 1 | none listed |
| XL-418 | Stopped | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 4 |
| Total on the list | 4 |